|
hepatocellular carcinoma |
63 |
|
humans |
44 |
|
medical sciences |
43 |
|
male |
33 |
|
middle aged |
32 |
|
adult |
31 |
|
aged |
31 |
|
cell line, tumor |
30 |
|
female |
30 |
|
hepatectomy |
25 |
|
prognosis |
25 |
|
survival analysis |
25 |
|
animals |
22 |
|
hcc |
22 |
|
gastroenterology |
21 |
|
aged, 80 and over |
19 |
|
reverse transcriptase polymerase chain reaction |
19 |
|
colorectal cancer |
18 |
|
disease-free survival |
18 |
|
sorafenib |
18 |
|
treatment outcome |
18 |
|
β-catenin |
18 |
|
carcinoma, hepatocellular - mortality - pathology - surgery |
17 |
|
mice |
17 |
|
mice, nude |
17 |
|
pin1 |
17 |
|
recurrence |
17 |
|
survival |
17 |
|
transfection |
17 |
|
advanced hepatocellular carcinoma |
16 |
|
cell proliferation |
16 |
|
liver cancer |
16 |
|
liver neoplasms - metabolism - pathology |
16 |
|
liver neoplasms - mortality - pathology - surgery |
16 |
|
carcinoma, hepatocellular - metabolism - pathology |
15 |
|
elderly |
15 |
|
metastasis |
15 |
|
carcinoma, hepatocellular - genetics - metabolism - pathology |
14 |
|
follow-up studies |
14 |
|
liver neoplasms - genetics - metabolism - pathology |
14 |
|
liver transplantation |
14 |
|
neoplasm invasiveness |
14 |
|
peptidyl-prolyl-isomerase |
14 |
|
retrospective studies |
14 |
|
surgery |
14 |
|
transarterial chemoembolization |
14 |
|
up-regulation |
14 |
|
ablation |
13 |
|
adolescent |
13 |
|
apoptosis |
13 |
|
child-pugh a |
13 |
|
cirrhosis |
13 |
|
gene expression regulation, neoplastic - genetics |
13 |
|
hepatectomy - methods |
13 |
|
carcinoma, hepatocellular - genetics |
12 |
|
cohort studies |
12 |
|
cytology and histology |
12 |
|
disease progression |
12 |
|
gastroenterology medical sciences |
12 |
|
gene expression regulation, neoplastic |
12 |
|
immunohistochemistry |
12 |
|
liver |
12 |
|
liver neoplasms - genetics |
12 |
|
radiofrequency ablation |
12 |
|
rna, messenger - metabolism |
12 |
|
age factors |
11 |
|
beta catenin |
11 |
|
carcinoma, hepatocellular - etiology - genetics - metabolism |
11 |
|
carcinoma, hepatocellular - genetics - metabolism - pathology - virology |
11 |
|
carcinoma, hepatocellular - mortality - surgery |
11 |
|
catheter ablation |
11 |
|
cyclin d1 - biosynthesis - genetics |
11 |
|
cytoskeletal proteins - genetics |
11 |
|
hepatitis b, chronic - complications |
11 |
|
liver neoplasms - genetics - metabolism - pathology - virology |
11 |
|
liver neoplasms - mortality - surgery |
11 |
|
multivariate analysis |
11 |
|
oncology medical sciences |
11 |
|
peptidylprolyl isomerase - biosynthesis - genetics |
11 |
|
radiology and nuclear medicine pharmacy and pharmacology biology |
11 |
|
trans-activators - genetics |
11 |
|
transplantation, heterologous |
11 |
|
advanced cancer |
10 |
|
advanced hcc |
10 |
|
alpps |
10 |
|
blotting, western |
10 |
|
bridging therapy |
10 |
|
carcinoma, hepatocellular - mortality - therapy |
10 |
|
carcinoma, hepatocellular - surgery |
10 |
|
hepatitis |
10 |
|
hepatitis b virus - physiology |
10 |
|
high-intensity focused ultrasound |
10 |
|
laparoscopic liver resection |
10 |
|
laparoscopy |
10 |
|
liver neoplasms - mortality - therapy |
10 |
|
liver neoplasms - surgery |
10 |
|
liver transplant |
10 |
|
neoplasm recurrence, local - surgery |
10 |
|
new technology |
10 |
|
palliative care |
10 |
|
portal vein |
10 |
|
resection |
10 |
|
risk factors |
10 |
|
time factors |
10 |
|
transcription, genetic |
10 |
|
allergology and immunology |
9 |
|
angiogenesis |
9 |
|
cancer invasion |
9 |
|
carcinoma, hepatocellular - virology |
9 |
|
case-control studies |
9 |
|
cell invasion |
9 |
|
endocrinology |
9 |
|
gene expression profiling |
9 |
|
hepatitis b - complications |
9 |
|
hifu |
9 |
|
liver neoplasms - virology |
9 |
|
morbidity |
9 |
|
mortality |
9 |
|
non-invasive treatment |
9 |
|
protein isoforms |
9 |
|
referral and consultation |
9 |
|
tumor cells, cultured |
9 |
|
tumor markers, biological - blood |
9 |
|
acetic acid c 11 |
8 |
|
adverse events |
8 |
|
base sequence |
8 |
|
bevacizumab |
8 |
|
bile ducts - surgery |
8 |
|
biomarker |
8 |
|
blood transfusion |
8 |
|
cadaver donor |
8 |
|
cancer cell culture |
8 |
|
cancer recurrence |
8 |
|
cancer survival |
8 |
|
carcinoma, hepatocellular - complications/diagnosis - surgery |
8 |
|
carcinoma, hepatocellular - metabolism - pathology - secondary |
8 |
|
carcinoma, hepatocellular - therapy |
8 |
|
catheter ablation - methods |
8 |
|
cell division - physiology |
8 |
|
cell movement |
8 |
|
cell transformation, neoplastic - genetics - metabolism |
8 |
|
chemoembolization, therapeutic - adverse effects - mortality |
8 |
|
child-pugh b |
8 |
|
cisplatin |
8 |
|
cyclin-dependent kinase inhibitor p16 - genetics - metabolism |
8 |
|
disease severity |
8 |
|
dna primers |
8 |
|
down-regulation |
8 |
|
down-regulation - drug effects |
8 |
|
fluorodeoxyglucose f 18 |
8 |
|
focal adhesion kinase 2 - metabolism |
8 |
|
gist |
8 |
|
hepatectomy - adverse effects |
8 |
|
hepatectomy - methods - mortality |
8 |
|
infusions, intra-arterial |
8 |
|
inhibitor of differentiation protein 1 |
8 |
|
laparoscopic resection |
8 |
|
liver cirrhosis |
8 |
|
liver metastasis |
8 |
|
liver neoplasms - complications/diagnosis - surgery |
8 |
|
liver neoplasms - pathology - surgery |
8 |
|
liver resection |
8 |
|
long-term outcome |
8 |
|
lymphatic metastasis |
8 |
|
medicine & public health |
8 |
|
microcirculation |
8 |
|
neovascularization, pathologic - metabolism |
8 |
|
oncology |
8 |
|
proportional hazards models |
8 |
|
rac gtp-binding proteins - metabolism |
8 |
|
repressor proteins |
8 |
|
retinoblastoma protein - genetics - metabolism |
8 |
|
rna, messenger - genetics - metabolism |
8 |
|
thrombosis - diagnosis - etiology - surgery |
8 |
|
tki |
8 |
|
transcription factors - genetics - metabolism - physiology |
8 |
|
tyrosine-kinase inhibitor |
8 |
|
xenograft model antitumor assays |
8 |
|
abdominal surgery |
7 |
|
american society of anaesthesiologists (asa) |
7 |
|
anti-angiogenesis |
7 |
|
antigen expression |
7 |
|
beta catenin - genetics |
7 |
|
cadherins - metabolism |
7 |
|
cancer combination chemotherapy |
7 |
|
cancer stem cell |
7 |
|
carcinoma |
7 |
|
carcinoma, hepatocellular - blood supply - drug therapy - pathology |
7 |
|
carcinoma, hepatocellular - diagnosis - pathology - surgery |
7 |
|
carcinoma, hepatocellular - drug therapy - physiopathology - secondary |
7 |
|
carcinoma, hepatocellular - enzymology - genetics |
7 |
|
carcinoma, hepatocellular - mortality - pathology - therapy |
7 |
|
cardiac surgery |
7 |
|
catheters, indwelling |
7 |
|
cell line |
7 |
|
cell proliferation - drug effects |
7 |
|
cell transformation, neoplastic - metabolism |
7 |
|
chemokine cxcl10 - metabolism |
7 |
|
cholecystitis, acute - surgery |
7 |
|
cholecystostomy - instrumentation - methods |
7 |
|
combined modality therapy |
7 |
|
combined resection |
7 |
|
cyclin d1 - genetics |
7 |
|
doxorubicin |
7 |
|
endothelial cells - drug effects |
7 |
|
epithelial cells - metabolism - physiology |
7 |
|
general surgery |
7 |
|
hepatitis b |
7 |
|
hepatitis b virus |
7 |
|
hepatitis b virus - genetics |
7 |
|
hepatocellular |
7 |
|
hepatocellular carcinoma (hcc) |
7 |
|
high-intensity focused ultrasound ablation - methods |
7 |
|
hypoxia-inducible factor 1, alpha subunit - metabolism |
7 |
|
indocyanine green clearance |
7 |
|
inhibitor of differentiation protein 1 - antagonists & inhibitors - genetics - metabolism |
7 |
|
invasiveness |
7 |
|
limon |
7 |
|
liver - pathology |
7 |
|
liver neoplasms - diagnosis - pathology - surgery |
7 |
|
liver neoplasms - drug therapy - physiopathology - secondary |
7 |
|
liver neoplasms - enzymology - genetics |
7 |
|
liver neoplasms - mortality - pathology - therapy |
7 |
|
liver neoplasms, experimental - blood supply - drug therapy - pathology |
7 |
|
logistic models |
7 |
|
matrix metalloproteinase 9 - metabolism |
7 |
|
microarray analysis - methods |
7 |
|
micrornas - genetics - metabolism |
7 |
|
neoplasm invasiveness - genetics |
7 |
|
neoplasm proteins - genetics |
7 |
|
neovascularization, pathologic - drug therapy |
7 |
|
nuclear proteins - metabolism |
7 |
|
oligodeoxyribonucleotides, antisense - pharmacology - therapeutic use |
7 |
|
peptidylprolyl isomerase - genetics |
7 |
|
percutaneous transhepatic cholecystostomy (ptc) |
7 |
|
proline-rich tyrosine kinase2 (pyk2) |
7 |
|
prospective studies |
7 |
|
pulse spectrophotometry |
7 |
|
recurrent hcc |
7 |
|
rna interference |
7 |
|
rna, neoplasm - genetics |
7 |
|
signal transduction |
7 |
|
spectrometry, mass, matrix-assisted laser desorption-ionization |
7 |
|
sphingosine - analogs & derivatives |
7 |
|
stat5 transcription factor - biosynthesis - genetics - metabolism |
7 |
|
statistics as topic |
7 |
|
structure-activity relationship |
7 |
|
survival rate |
7 |
|
targeted therapy |
7 |
|
thalidomide |
7 |
|
thoracic surgery |
7 |
|
tissue array analysis |
7 |
|
transcriptional activation - physiology |
7 |
|
transfection - methods |
7 |
|
tumor |
7 |
|
tumor markers, biological - analysis |
7 |
|
twist transcription factor - metabolism |
7 |
|
up-regulation - genetics |
7 |
|
usg-guided |
7 |
|
vascular endothelial growth factor |
7 |
|
vascular endothelial growth factor a - blood |
7 |
|
vascular endothelial growth factor a - genetics - metabolism - secretion |
7 |
|
vascular endothelial growth factors |
7 |
|
vascular surgery |
7 |
|
virus replication |
7 |
|
afp |
6 |
|
akt signaling pathway |
6 |
|
amino acid motifs |
6 |
|
analysis of variance |
6 |
|
antigens, cd34 - metabolism |
6 |
|
antineoplastic agents - adverse effects - therapeutic use |
6 |
|
antineoplastic agents, hormonal - administration & dosage |
6 |
|
antiviral therapy |
6 |
|
asian |
6 |
|
bcl-x protein - genetics - metabolism |
6 |
|
biomarkers |
6 |
|
cadherins - genetics - metabolism |
6 |
|
cancer staging |
6 |
|
carcinoma, hepatocellular - blood - metabolism |
6 |
|
carcinoma, hepatocellular - diagnosis - therapy |
6 |
|
carcinoma, hepatocellular - drug therapy - metabolism - secondary |
6 |
|
carcinoma, hepatocellular - drug therapy - mortality |
6 |
|
carcinoma, hepatocellular - drug therapy - pathology - surgery - virology |
6 |
|
carcinoma, hepatocellular - enzymology - pathology |
6 |
|
carcinoma, hepatocellular - etiology - pathology - surgery - virology |
6 |
|
carcinoma, hepatocellular - genetics - mortality - pathology - surgery - therapy |
6 |
|
carcinoma, hepatocellular - genetics - prevention and control - secondary |
6 |
|
cdna microarray |
6 |
|
cell cycle - genetics |
6 |
|
cell cycle proteins - genetics |
6 |
|
chemocytotoxic |
6 |
|
chemoembolization, therapeutic |
6 |
|
cholangiocarcinoma |
6 |
|
chromosome 8p |
6 |
|
complex liver resection |
6 |
|
complication |
6 |
|
controlled study |
6 |
|
cyclin-dependent kinase inhibitor p21 |
6 |
|
data mining |
6 |
|
deceased donor liver transplantation |
6 |
|
disease models, animal |
6 |
|
dkk1 |
6 |
|
dna, viral - analysis |
6 |
|
enhancer elements (genetics) - genetics |
6 |
|
enzyme-linked immunosorbent assay |
6 |
|
erlotinib |
6 |
|
family history |
6 |
|
fatal outcome |
6 |
|
focal adhesion kinase |
6 |
|
fty720 |
6 |
|
genes, p53 - genetics |
6 |
|
genetic association |
6 |
|
gold(iii) compound |
6 |
|
growth arrest and dna damage (gadd) inducible genes |
6 |
|
hepatic veins - pathology |
6 |
|
hepatitis b - complications - genetics - metabolism - pathology - virology |
6 |
|
hepatitis b virus - isolation and purification |
6 |
|
homeodomain proteins - antagonists and inhibitors - genetics - metabolism |
6 |
|
homeodomain proteins - genetics - metabolism |
6 |
|
homeoprotein six1 |
6 |
|
hong kong - epidemiology |
6 |
|
immunosuppressive agents - therapeutic use |
6 |
|
inoperable |
6 |
|
intercellular signaling peptides and proteins - blood - metabolism |
6 |
|
interference |
6 |
|
interferon-alpha - adverse effects - therapeutic use |
6 |
|
kidney neoplasms - genetics - prevention and control - secondary |
6 |
|
liver - blood supply - metabolism - pathology - surgery |
6 |
|
liver carcinogenesis |
6 |
|
liver neoplasms - blood - metabolism |
6 |
|
liver neoplasms - diagnosis - therapy |
6 |
|
liver neoplasms - drug therapy - mortality |
6 |
|
liver neoplasms - drug therapy - pathology - surgery - virology |
6 |
|
liver neoplasms - enzymology - pathology |
6 |
|
liver neoplasms - etiology - pathology - surgery - virology |
6 |
|
liver neoplasms - genetics - mortality - pathology - surgery - therapy |
6 |
|
liver neoplasms, experimental - drug therapy - metabolism - pathology |
6 |
|
liver neoplasms, experimental - genetics - pathology - prevention and control |
6 |
|
liver neoplasms, experimental - metabolism - pathology - surgery |
6 |
|
liver neoplasms, experimental - metabolism - pathology - virology |
6 |
|
lung metastasis |
6 |
|
lung neoplasms - etiology - metabolism - secondary |
6 |
|
map kinase signaling system - drug effects |
6 |
|
molecular targeted therapy |
6 |
|
neoplasm metastasis |
6 |
|
neoplasm recurrence, local - etiology - metabolism - pathology |
6 |
|
neoplasm staging |
6 |
|
neovascularization, pathologic - prevention & control |
6 |
|
octreotide - administration & dosage |
6 |
|
pathologic tumour-node-metastasis (ptnm) stage |
6 |
|
peptidylprolyl isomerase - genetics - metabolism |
6 |
|
phosphatidylinositol 3-kinases - antagonists & inhibitors - metabolism |
6 |
|
phosphorylation |
6 |
|
placebos |
6 |
|
postoperative complications |
6 |
|
proliferating cell nuclear antigen - analysis |
6 |
|
proline |
6 |
|
promoter regions (genetics) - genetics |
6 |
|
propylene glycols - pharmacology |
6 |
|
propylene glycols - therapeutic use |
6 |
|
protein binding |
6 |
|
proteomic profiling |
6 |
|
proto-oncogene proteins c-myc - genetics - metabolism |
6 |
|
rac gtp-binding proteins - chemistry - metabolism |
6 |
|
radiofrequency |
6 |
|
recurrent hepatocellular carcinoma |
6 |
|
reoperation |
6 |
|
reproducibility of results |
6 |
|
risk factor |
6 |
|
rna, small interfering - pharmacology |
6 |
|
salvage therapy |
6 |
|
serine |
6 |
|
short hairpin rna (shrna) |
6 |
|
signal transduction - physiology |
6 |
|
simultaneous resection |
6 |
|
six1 |
6 |
|
sorafenib-refractory |
6 |
|
stage resection |
6 |
|
synchronous colorectal liver metastasis |
6 |
|
trans-activators - genetics - metabolism |
6 |
|
transcription factor rela - genetics - metabolism |
6 |
|
transcriptional activation |
6 |
|
tumor markers, biological - blood - metabolism |
6 |
|
vascular endothelial growth factor a - metabolism |
6 |
|
venous infiltration |
6 |
|
wnt |
6 |
|
wound healing |
6 |
|
5-fu |
5 |
|
academic medical centers |
5 |
|
acute disease |
5 |
|
aggressiveness |
5 |
|
alpha-fetoprotein |
5 |
|
animal experiment |
5 |
|
animal models |
5 |
|
antineoplastic agents - therapeutic use |
5 |
|
antineoplastic agents, hormonal - therapeutic use |
5 |
|
area under curve |
5 |
|
biopsy, needle - adverse effects - methods |
5 |
|
blood loss, surgical |
5 |
|
cancer biomarker |
5 |
|
carcinogenicity |
5 |
|
carcinoma, hepatocellular - blood - blood supply - pathology |
5 |
|
carcinoma, hepatocellular - chemistry - drug therapy - mortality |
5 |
|
carcinoma, hepatocellular - complications - diagnosis - surgery |
5 |
|
carcinoma, hepatocellular - complications - pathology - surgery |
5 |
|
carcinoma, hepatocellular - diagnosis - mortality |
5 |
|
carcinoma, hepatocellular - enzymology - pathology - ultrastructure |
5 |
|
carcinoma, hepatocellular - metabolism - mortality - secondary |
5 |
|
carcinoma, hepatocellular - pathology - surgery |
5 |
|
carcinoma, squamous cell - genetics - pathology |
5 |
|
carrier proteins - genetics |
5 |
|
catheter ablation - adverse effects |
5 |
|
cdh17 |
5 |
|
cdh17/β-catenin axis |
5 |
|
cell assay |
5 |
|
cell cycle |
5 |
|
cell growth |
5 |
|
cell movement - physiology |
5 |
|
chemoresistanc |
5 |
|
chemosensitivity |
5 |
|
chemotherapy |
5 |
|
chi-square distribution |
5 |
|
cholangiocarcinoma - complications - pathology - surgery |
5 |
|
cholangiopancreatography, endoscopic retrograde - methods |
5 |
|
cholelithiasis - complications - diagnosis - surgery |
5 |
|
chronic disease |
5 |
|
clinical competence |
5 |
|
confidence intervals |
5 |
|
cryotherapy |
5 |
|
deleted in liver cancer 1 |
5 |
|
dna, circular - analysis - isolation & purification |
5 |
|
dna, viral - analysis - isolation & purification |
5 |
|
e-cadherin |
5 |
|
endoscopic retrograde cholangiopancreatography |
5 |
|
endoscopic sphicterotomy |
5 |
|
endosonography |
5 |
|
endothelial growth factors - blood |
5 |
|
enzyme activity |
5 |
|
epigenesis, genetic |
5 |
|
epithelial-mesenchymal transition - physiology |
5 |
|
esomeprazole |
5 |
|
extracellular signal-regulated map kinases - metabolism |
5 |
|
fascin |
5 |
|
focal adhesion kinase 2 - metabolism - physiology |
5 |
|
gallstones - complications - ultrasonography |
5 |
|
gastrointestinal hemorrhage |
5 |
|
gene expression regulation, viral |
5 |
|
graft survival |
5 |
|
gsk3β |
5 |
|
gtpase-activating proteins |
5 |
|
hemostasis |
5 |
|
hepatic steatosis |
5 |
|
hepatic stellate cell |
5 |
|
hepatic stellate cells |
5 |
|
hepatitis b surface antigens - metabolism |
5 |
|
hepatitis b, chronic - complications - virology |
5 |
|
hepatology |
5 |
|
hippo signaling |
5 |
|
human recombinant arginase |
5 |
|
iatrogenic disease |
5 |
|
iatrogenic disease - prevention and control |
5 |
|
internal medicine |
5 |
|
intraoperative complications |
5 |
|
isoforms |
5 |
|
length of stay |
5 |
|
liver - virology |
5 |
|
liver cell carcinoma |
5 |
|
liver cirrhosis - complications |
5 |
|
liver cirrhosis - complications - virology |
5 |
|
liver embryo |
5 |
|
liver neoplasms - blood - blood supply - pathology |
5 |
|
liver neoplasms - chemistry - drug therapy - mortality |
5 |
|
liver neoplasms - complications - diagnosis - surgery |
5 |
|
liver neoplasms - complications - pathology - surgery |
5 |
|
liver neoplasms - complications - surgery |
5 |
|
liver neoplasms - diagnosis - mortality |
5 |
|
liver neoplasms - drug therapy - pathology |
5 |
|
liver neoplasms - enzymology - pathology - ultrastructure |
5 |
|
liver neoplasms - metabolism - mortality - pathology |
5 |
|
liver neoplasms - therapy |
5 |
|
liver remnant |
5 |
|
liver transplantation - methods |
5 |
|
lobectomy |
5 |
|
lymphokines - blood |
5 |
|
marginal graft |
5 |
|
matrix metalloproteinase-12 |
5 |
|
medical errors - adverse effects |
5 |
|
metachronous primary hcc |
5 |
|
microfilament proteins - genetics |
5 |
|
micrornas - metabolism |
5 |
|
microsatellite repeats |
5 |
|
mouth neoplasms - genetics - pathology |
5 |
|
multidrug resistance protein 1 |
5 |
|
neoplasm recurrence, local - mortality |
5 |
|
neoplasm recurrence, local - mortality - pathology |
5 |
|
neoplasm seeding |
5 |
|
neoplasms, second primary - mortality - surgery |
5 |
|
neoplastic cells, circulating - pathology |
5 |
|
neovascularization, pathologic |
5 |
|
non-coding rna |
5 |
|
novel therapy |
5 |
|
nuclear proteins - analysis |
5 |
|
oncofetal proteins |
5 |
|
oscc |
5 |
|
outcome |
5 |
|
oxaliplatin |
5 |
|
palliative care - methods |
5 |
|
pancreaticoduodenectomy - mortality - standards |
5 |
|
pancreatitis - etiology - ultrasonography |
5 |
|
pancreatitis, acute necrotizing - diagnosis - etiology - surgery |
5 |
|
papillotomy |
5 |
|
platelet count |
5 |
|
postoperative care |
5 |
|
preclinical study |
5 |
|
predictive value of tests |
5 |
|
preoperative care - methods |
5 |
|
probability |
5 |
|
proctology |
5 |
|
prognostic marker |
5 |
|
ptk787 |
5 |
|
quality of life |
5 |
|
radiography, abdominal |
5 |
|
receptors, estrogen - analysis |
5 |
|
receptors, progesterone - analysis |
5 |
|
reference values |
5 |
|
renal transplantation |
5 |
|
residual |
5 |
|
rho-associated kinases - analysis - metabolism |
5 |
|
rhoa |
5 |
|
rhoc |
5 |
|
risk assessment |
5 |
|
rna, messenger - analysis - isolation & purification |
5 |
|
rna, viral - analysis - isolation & purification |
5 |
|
rupture - etiology - mortality - pathology |
5 |
|
segmentectomy |
5 |
|
single-blind method |
5 |
|
slit3 |
5 |
|
smoking |
5 |
|
spink1 |
5 |
|
spleen - injuries - pathology - radiography - surgery |
5 |
|
surgery medical sciences |
5 |
|
surrogate |
5 |
|
survival rate - trends |
5 |
|
survivin |
5 |
|
tamoxifen - therapeutic use |
5 |
|
toce |
5 |
|
transcription factors - analysis |
5 |
|
tumor markers |
5 |
|
tumor markers, biological - metabolism |
5 |
|
tumor progression |
5 |
|
tumor recurrence |
5 |
|
tumor stem cell assay |
5 |
|
tumor suppressor proteins - genetics - metabolism |
5 |
|
tumorigenesis |
5 |
|
vascular endothelial growth factor a |
5 |
|
wedge resection |
5 |
|
yes-associated protein |
5 |
|
young adult |
5 |
|
adaptor proteins, signal transducing - metabolism |
4 |
|
antigens, cd34 - analysis |
4 |
|
antineoplastic combined chemotherapy protocols - pharmacology |
4 |
|
antiviral agents - therapeutic use |
4 |
|
basic fibroblast growth factor |
4 |
|
biomedical research |
4 |
|
cadherin-17 |
4 |
|
cancer |
4 |
|
cancer screening |
4 |
|
carboxypeptidase h - chemistry - genetics |
4 |
|
carcinoma, hepatocellular - blood - chemistry - diagnosis |
4 |
|
carcinoma, hepatocellular - blood - diagnosis - pathology |
4 |
|
carcinoma, hepatocellular - blood - mortality - pathology - surgery |
4 |
|
carcinoma, hepatocellular - blood - surgery |
4 |
|
carcinoma, hepatocellular - blood supply - immunology |
4 |
|
carcinoma, hepatocellular - classification - pathology - surgery |
4 |
|
carcinoma, hepatocellular - complications - metabolism |
4 |
|
carcinoma, hepatocellular - complications - mortality - surgery |
4 |
|
carcinoma, hepatocellular - diagnosis - genetics - metabolism - pathology |
4 |
|
carcinoma, hepatocellular - drug therapy - pathology - surgery |
4 |
|
carcinoma, hepatocellular - epidemiology - etiology - pathology |
4 |
|
carcinoma, hepatocellular - genetics - metabolism |
4 |
|
carcinoma, hepatocellular - genetics - mortality |
4 |
|
carcinoma, hepatocellular - genetics - pathology - virology |
4 |
|
carcinoma, hepatocellular - pathology - radiography - surgery |
4 |
|
carcinoma, hepatocellular - pathology - surgery - virology |
4 |
|
carcinoma, hepatocellular - pathology - therapy |
4 |
|
carcinoma, hepatocellular - radiography - surgery |
4 |
|
carcinoma, squamous cell - drug therapy - genetics - metabolism - pathology |
4 |
|
cardia |
4 |
|
catheter ablation - instrumentation - methods |
4 |
|
catheter ablation - standards - statistics & numerical data |
4 |
|
cell death - drug effects |
4 |
|
cell growth processes - drug effects |
4 |
|
cell line establishment |
4 |
|
cell migration |
4 |
|
cell movement - drug effects |
4 |
|
cgh |
4 |
|
chemotherapy, adjuvant |
4 |
|
cholangiocarcinoma - therapy |
4 |
|
chromosome aberrations |
4 |
|
chromosomes, human, pair 14 - genetics |
4 |
|
cisplatin - administration & dosage - pharmacology |
4 |
|
clinical competence - standards - statistics & numerical data |
4 |
|
codon |
4 |
|
complement c4 - metabolism |
4 |
|
contraceptives, oral - administration & dosage |
4 |
|
diabetes complications |
4 |
|
diagnosis |
4 |
|
diagnosis and prognosis |
4 |
|
dna copy number variations |
4 |
|
dna, neoplasm - genetics |
4 |
|
drug synergism |
4 |
|
eif5a |
4 |
|
electrophoresis, gel, two-dimensional |
4 |
|
epithelial cells - drug effects - pathology |
4 |
|
esophageal neoplasms - psychology - surgery |
4 |
|
family practice - trends |
4 |
|
fibroblast growth factor 2 - blood |
4 |
|
fibrosis progression |
4 |
|
forecasting |
4 |
|
gallbladder |
4 |
|
gene regulatory networks - genetics |
4 |
|
genotype |
4 |
|
granulin-epithelin precursor |
4 |
|
head and neck neoplasms - drug therapy - genetics - metabolism - pathology |
4 |
|
hepatectomy - adverse effects - methods - mortality |
4 |
|
hepatectomy - statistics and numerical data |
4 |
|
hepatitis b - complications - pathology - surgery |
4 |
|
hepatitis b antibodies - analysis |
4 |
|
hepatitis b e antigens - analysis |
4 |
|
hepatitis b surface antigens - analysis |
4 |
|
hepatitis b surface antigens - blood - metabolism |
4 |
|
hepatitis b virus - genetics - immunology |
4 |
|
hepatitis b virus - isolation & purification |
4 |
|
hepatitis b, chronic - drug therapy - pathology - virology |
4 |
|
hepatitis b, chronic - metabolism - physiopathology |
4 |
|
hypusination |
4 |
|
i-kappa b kinase - genetics - metabolism |
4 |
|
image interpretation, computer-assisted |
4 |
|
incidence |
4 |
|
intercellular signaling peptides and proteins - genetics |
4 |
|
intolerance |
4 |
|
intrahepatic metastasis |
4 |
|
iodide peroxidase - genetics |
4 |
|
laparoscopic ultrasonography |
4 |
|
laparoscopy - statistics and numerical data |
4 |
|
large |
4 |
|
liver - cytology - metabolism - pathology |
4 |
|
liver - metabolism |
4 |
|
liver - metabolism - pathology |
4 |
|
liver cirrhosis - epidemiology - etiology - pathology |
4 |
|
liver cirrhosis - genetics |
4 |
|
liver function tests |
4 |
|
liver neoplasms - blood - chemistry - diagnosis |
4 |
|
liver neoplasms - blood - diagnosis - pathology |
4 |
|
liver neoplasms - blood - mortality - pathology - surgery |
4 |
|
liver neoplasms - blood - surgery |
4 |
|
liver neoplasms - blood supply - immunology |
4 |
|
liver neoplasms - classification - mortality - pathology - surgery |
4 |
|
liver neoplasms - complications - metabolism |
4 |
|
liver neoplasms - complications - mortality - surgery |
4 |
|
liver neoplasms - diagnosis - genetics - metabolism - pathology |
4 |
|
liver neoplasms - drug therapy - pathology - surgery |
4 |
|
liver neoplasms - epidemiology - etiology - pathology |
4 |
|
liver neoplasms - genetics - metabolism |
4 |
|
liver neoplasms - genetics - mortality |
4 |
|
liver neoplasms - genetics - pathology - secondary - virology |
4 |
|
liver neoplasms - pathology - radiography - surgery |
4 |
|
liver neoplasms - pathology - surgery - virology |
4 |
|
liver neoplasms - pathology - therapy |
4 |
|
liver neoplasms - radiography - surgery |
4 |
|
liver neoplasms - secondary - therapy |
4 |
|
liver transplantation - methods - mortality |
4 |
|
loh |
4 |
|
loss of heterozygosity |
4 |
|
mannose-binding lectin - blood - genetics - metabolism |
4 |
|
membrane proteins - genetics |
4 |
|
mesoderm - drug effects - pathology |
4 |
|
microarray |
4 |
|
mir-122 |
4 |
|
mitochondrial |
4 |
|
molecular relationship |
4 |
|
multicentric occurrence |
4 |
|
multigene family |
4 |
|
multinodular |
4 |
|
neoplasm proteins - analysis - blood |
4 |
|
neoplasm recurrence, local - blood supply |
4 |
|
neoplasm recurrence, local - mortality - pathology - surgery |
4 |
|
neoplastic stem cells - pathology |
4 |
|
nf-kappa b - antagonists & inhibitors - biosynthesis - genetics - metabolism |
4 |
|
nuclear proteins - genetics - metabolism |
4 |
|
nucleic acid hybridization |
4 |
|
occult hbv co-infection |
4 |
|
octreotide |
4 |
|
oncofetal molecule |
4 |
|
oncogene |
4 |
|
p27 |
4 |
|
pancreatic anastomotic leakage |
4 |
|
pancreaticoduodenectomy |
4 |
|
pattern |
4 |
|
pentacyclic triterpenes |
4 |
|
peptide initiation factors - antagonists and inhibitors - genetics - metabolism |
4 |
|
polymorphism, genetic |
4 |
|
portal vein - pathology - radiography - surgery |
4 |
|
protein array analysis |
4 |
|
protein structure, tertiary |
4 |
|
proteome - metabolism |
4 |
|
proteomics |
4 |
|
proteomics - methods |
4 |
|
proteomics - methods - trends |
4 |
|
proto-oncogene proteins c-met - genetics |
4 |
|
rats |
4 |
|
recurrent chronic hepatitis c virus |
4 |
|
relapsed infection due to hbv |
4 |
|
resectability |
4 |
|
respiratory diseases |
4 |
|
rhoa-gtp |
4 |
|
rna-binding proteins - antagonists and inhibitors - genetics - metabolism |
4 |
|
ruptured hepatocellular carcinoma |
4 |
|
severe fibrosis |
4 |
|
severity of illness index |
4 |
|
single institution |
4 |
|
statistics, nonparametric |
4 |
|
stomach neoplasms - psychology - surgery |
4 |
|
tandem mass spectrometry |
4 |
|
therapeutic target |
4 |
|
tissue distribution |
4 |
|
tolerance |
4 |
|
tomography, x-ray computed |
4 |
|
transcriptome |
4 |
|
triterpenes - administration & dosage - pharmacology |
4 |
|
tumor biomarker |
4 |
|
tumor detection |
4 |
|
tumor markers, biological - analysis - blood |
4 |
|
tumor markers, biological - genetics - metabolism |
4 |
|
tumor size |
4 |
|
urology and nephrology |
4 |
|
vascular endothelial growth factors - biosynthesis - metabolism |
4 |
|
vimentin - blood |
4 |
|
virus integration |
4 |
|
wnt signaling |
4 |
|
3-month overall survival |
3 |
|
abdominal pain |
3 |
|
actins - metabolism |
3 |
|
adenosine triphosphate - analysis |
3 |
|
advanced liver cancer prognostic system |
3 |
|
alanine aminotransferase blood level |
3 |
|
alanine transaminase - blood |
3 |
|
alanine transaminase - metabolism |
3 |
|
algorithms |
3 |
|
allograft inflammatory factor-1 |
3 |
|
alpha-fetoproteins - metabolism |
3 |
|
angiogenesis inducing agents - metabolism |
3 |
|
angiogenesis inhibitors - therapeutic use |
3 |
|
angiosperms |
3 |
|
antiangiogenic therapy |
3 |
|
antineoplastic combined chemotherapy protocols - administration & dosage |
3 |
|
aspartate aminotransferases - blood |
3 |
|
associating liver partition and portal vein ligation for stage hepatectomy |
3 |
|
atp-binding cassette transporters - physiology |
3 |
|
attitude of health personnel |
3 |
|
axl receptor kinase |
3 |
|
bile duct neoplasms - radiotherapy |
3 |
|
bile ducts, intrahepatic |
3 |
|
biliary obstruction |
3 |
|
biological markers - blood |
3 |
|
blood transfusion, autologous |
3 |
|
brachytherapy |
3 |
|
cancer signaling |
3 |
|
carbon tetrachloride |
3 |
|
carcinoma, hepatocellular - blood - diagnosis - pathology - therapy |
3 |
|
carcinoma, hepatocellular - blood - mortality |
3 |
|
carcinoma, hepatocellular - blood supply - pathology - surgery |
3 |
|
carcinoma, hepatocellular - drug therapy |
3 |
|
carcinoma, hepatocellular - drug therapy - genetics - metabolism |
3 |
|
carcinoma, hepatocellular - drug therapy - mortality - pathology |
3 |
|
carcinoma, hepatocellular - genetics - virology |
3 |
|
carcinoma, hepatocellular - mortality - pathology - surgery - therapy |
3 |
|
carcinoma, hepatocellular - mortality - pathology - virology |
3 |
|
carcinoma, hepatocellular - secondary - surgery |
3 |
|
cell division |
3 |
|
cell survival - physiology |
3 |
|
checkpoint |
3 |
|
cholangiocarcinoma - complications - mortality - surgery |
3 |
|
cholangiocarcinoma - radiotherapy |
3 |
|
cholangiopancreatography, endoscopic retrograde - adverse effects |
3 |
|
collagen - metabolism |
3 |
|
colorectal neoplasms - secondary |
3 |
|
complications |
3 |
|
dickkopfs |
3 |
|
dna damage - genetics - physiology |
3 |
|
dna, neoplasm - analysis |
3 |
|
dose-response relationship, drug |
3 |
|
double-blind method |
3 |
|
drug combinations |
3 |
|
drug resistance, neoplasm - physiology |
3 |
|
drugs, chinese herbal - pharmacology - therapeutic use |
3 |
|
duodenal |
3 |
|
duodenal diseases - etiology |
3 |
|
electrodes |
3 |
|
embryonal carcinoma cell |
3 |
|
embryonal carcinoma stem cells - cytology - metabolism |
3 |
|
emt |
3 |
|
endothelial growth factors - biosynthesis - genetics |
3 |
|
endothelial growth factors - genetics - metabolism |
3 |
|
endothelial growth factors - metabolism |
3 |
|
equipment design |
3 |
|
esophageal cancer |
3 |
|
extracellular matrix proteins - genetics - metabolism |
3 |
|
flk-1/kdr |
3 |
|
flow cytometry |
3 |
|
flt-1 |
3 |
|
fuzheng huayu recipe |
3 |
|
g2 phase - genetics |
3 |
|
gastric cancer |
3 |
|
gastrointestinal neoplasms - blood supply - drug therapy - metabolism |
3 |
|
genetic aberrations |
3 |
|
haematoma |
3 |
|
hbx protein |
3 |
|
hemostasis, surgical - methods |
3 |
|
hepatectomy - instrumentation - methods |
3 |
|
hepatic fibrosis |
3 |
|
hepatic stellate cells - metabolism |
3 |
|
hepatitis b - pathology |
3 |
|
hepatitis c virus |
3 |
|
hepatoblastoma |
3 |
|
hevin |
3 |
|
hilar cholangiocarcinoma |
3 |
|
hippo pathway |
3 |
|
histologic activity index |
3 |
|
hormones - administration & dosage |
3 |
|
hsp70 heat-shock proteins - antagonists and inhibitors - metabolism |
3 |
|
human hepatocellular carcinoma |
3 |
|
immunoenzyme techniques |
3 |
|
immunologic factors - therapeutic use |
3 |
|
in situ hybridization |
3 |
|
in-situ split |
3 |
|
intercellular signaling peptides and proteins - biosynthesis - genetics |
3 |
|
intercellular signaling peptides and proteins - metabolism |
3 |
|
interleukin-8 - biosynthesis - genetics |
3 |
|
interstitial laser therapy |
3 |
|
intestinal fistula - etiology |
3 |
|
intramural |
3 |
|
ionizing radiation |
3 |
|
lithiasis - complications - surgery |
3 |
|
liver - drug effects - metabolism - pathology |
3 |
|
liver - pathology - surgery |
3 |
|
liver cirrhosis - chemically induced - metabolism - prevention & control |
3 |
|
liver cirrhosis - pathology |
3 |
|
liver diseases - complications - surgery |
3 |
|
liver neoplasms |
3 |
|
liver neoplasms - blood - diagnosis |
3 |
|
liver neoplasms - blood - mortality |
3 |
|
liver neoplasms - blood supply - pathology - surgery |
3 |
|
liver neoplasms - drug therapy |
3 |
|
liver neoplasms - genetics - virology |
3 |
|
liver neoplasms - mortality - pathology - surgery - therapy |
3 |
|
liver neoplasms - mortality - pathology - virology |
3 |
|
liver transplantation - immunology |
3 |
|
living donors |
3 |
|
lymphokines - biosynthesis - genetics |
3 |
|
lymphokines - genetics - metabolism |
3 |
|
lymphokines - metabolism |
3 |
|
macrophage activation - immunology |
3 |
|
macrophage migration inhibitory factor |
3 |
|
macrophage migration-inhibitory factors - pharmacology - physiology |
3 |
|
macrophages |
3 |
|
macrophages - immunology |
3 |
|
malignant liver tumor |
3 |
|
medicine, chinese traditional |
3 |
|
micrornas - genetics |
3 |
|
microvessel density |
3 |
|
microwave coagulation therapy |
3 |
|
mortalin |
3 |
|
mortalin-p53 interaction |
3 |
|
mutant p53-dependent apoptosis |
3 |
|
neoplasm recurrence, local |
3 |
|
neoplasm recurrence, local - prevention & control - therapy |
3 |
|
neoplasm recurrence, local - therapy |
3 |
|
neoplasms - metabolism - mortality - therapy |
3 |
|
neoplasms - pathology |
3 |
|
neovascularization, pathologic - blood - diagnosis |
3 |
|
notch signaling |
3 |
|
octamer transcription factor-3 - physiology |
3 |
|
organ culture techniques |
3 |
|
origin |
3 |
|
pancreatic |
3 |
|
pancreatic cancer |
3 |
|
pancreatitis - blood - etiology - prevention & control |
3 |
|
pdgf |
3 |
|
phytotherapy |
3 |
|
platelet-derived growth factor - genetics - metabolism |
3 |
|
pleural diseases - etiology |
3 |
|
prognostic score system |
3 |
|
proteome - analysis |
3 |
|
proto-oncogene proteins - genetics - metabolism |
3 |
|
radioembolization |
3 |
|
radix salviae miltiorrhizae |
3 |
|
rats, sprague-dawley |
3 |
|
receptor protein-tyrosine kinases - genetics - metabolism |
3 |
|
receptors, growth factor - genetics - metabolism |
3 |
|
receptors, vascular endothelial growth factor |
3 |
|
respiratory tract fistula - etiology |
3 |
|
responses |
3 |
|
rna, neoplasm - metabolism |
3 |
|
rnai |
3 |
|
s phase - genetics |
3 |
|
serum albumin - analysis |
3 |
|
signal transduction - genetics |
3 |
|
sodium chloride |
3 |
|
somatostatin - administration & dosage |
3 |
|
sparc |
3 |
|
spectrometry, mass, matrix-assisted laser desorption-ionization - methods |
3 |
|
stress |
3 |
|
stress, physiological |
3 |
|
subcapsular carcinoma |
3 |
|
swine |
3 |
|
systemic |
3 |
|
target |
3 |
|
temperature |
3 |
|
tgf-β1 |
3 |
|
thalidomide - therapeutic use |
3 |
|
therapy |
3 |
|
thermal ablative therapy |
3 |
|
thymidine phosphorylase - blood |
3 |
|
timp-1 |
3 |
|
tissue culture techniques |
3 |
|
tissue inhibitor of metalloproteinase-1 - genetics - metabolism |
3 |
|
traditional chinese medicine |
3 |
|
transforming growth factor beta - blood |
3 |
|
transforming growth factor beta1 - metabolism |
3 |
|
tuberculosis |
3 |
|
tumor cells, cultured - metabolism - pathology |
3 |
|
tumor suppressor protein p53 - genetics - metabolism |
3 |
|
vascular endothelial growth factor a - biosynthesis - immunology |
3 |
|
vascular endothelial growth factor receptor-1 |
3 |
|
vascular endothelial growth factor receptor-2 - biosynthesis - immunology |
3 |
|
vegf |
3 |
|
venous thrombosis - etiology |
3 |
|
yap1 oncogene |
3 |
|
abdominal distension |
2 |
|
actins - genetics - metabolism |
2 |
|
actuarial analysis |
2 |
|
adaptor proteins, signal transducing - genetics - metabolism |
2 |
|
akt |
2 |
|
alopecia |
2 |
|
alpha-fetoproteins - analysis |
2 |
|
anemia |
2 |
|
animal cell |
2 |
|
anti-inflammatory agents, non-steroidal - pharmacology |
2 |
|
antigens, cd18 - therapeutic use |
2 |
|
antineoplastic agents - pharmacology |
2 |
|
apoptosis - drug effects |
2 |
|
atrial thrombosis |
2 |
|
bacterial endotoxin |
2 |
|
biological factors |
2 |
|
biology |
2 |
|
biotherapeutic peptide |
2 |
|
brain derived neurotrophic factor |
2 |
|
brain-derived neurotrophic factor |
2 |
|
broviac |
2 |
|
cancer stem cells |
2 |
|
carcinogenesis |
2 |
|
carcinoma, hepatocellular - drug therapy - pathology |
2 |
|
carcinoma, hepatocellular - genetics - pathology - therapy |
2 |
|
carcinoma, hepatocellular - pathology - secondary - surgery |
2 |
|
carcinoma, hepatocellular - secondary - therapy |
2 |
|
cardiotrophin-1 |
2 |
|
caspase 3 |
2 |
|
caspases - metabolism |
2 |
|
cell hypoxia |
2 |
|
cellcycle |
2 |
|
chaperonin 60 - genetics - metabolism |
2 |
|
chemokine receptor |
2 |
|
chemoresistance |
2 |
|
child |
2 |
|
child, preschool |
2 |
|
china |
2 |
|
cholangiopancreatography, endoscopic retrograde |
2 |
|
circulating mrna |
2 |
|
cisplatin - therapeutic use |
2 |
|
cxcr3 ligands |
2 |
|
cyclooxygenase 2 - biosynthesis |
2 |
|
cyclooxygenase 2 inhibitors - therapeutic use |
2 |
|
cyclooxygenase-2 |
2 |
|
databases, factual |
2 |
|
early hcc |
2 |
|
electrophoresis, gel, two-dimensional - methods - standards |
2 |
|
embolization |
2 |
|
embolization, therapeutic - methods |
2 |
|
endoglin |
2 |
|
endoscopic sphincterotomy |
2 |
|
endotoxins - antagonists and inhibitors - blood |
2 |
|
energy metabolism - physiology |
2 |
|
enteral nutrition |
2 |
|
epidemiology |
2 |
|
epidermal growth factor |
2 |
|
epidermal growth factor receptor inhibitors |
2 |
|
extrahepatic metastases |
2 |
|
gene expression |
2 |
|
hemoglobinuria |
2 |
|
hemolysis |
2 |
|
hepatectomy - mortality |
2 |
|
hepatic artery |
2 |
|
hepatic resection |
2 |
|
hepatic vein |
2 |
|
hickman |
2 |
|
hsp90 heat-shock proteins - metabolism |
2 |
|
hypoxia inducible factor-1α |
2 |
|
hypoxia-inducible factor 1, alpha subunit |
2 |
|
indocyanine green clearance test |
2 |
|
inflammation |
2 |
|
integrin cd18 |
2 |
|
intratumoral microvessel density |
2 |
|
lamin type b - blood - genetics |
2 |
|
liver - cancer - prognosis. |
2 |
|
liver - cancer - relapse. |
2 |
|
liver - cancer - surgery. |
2 |
|
liver - surgery |
2 |
|
liver cirrhosis - complications - metabolism - virology |
2 |
|
liver cirrhosis - complications - pathology |
2 |
|
liver failure |
2 |
|
liver fibrosis |
2 |
|
liver function |
2 |
|
liver neoplasms - blood - genetics |
2 |
|
liver neoplasms - drug therapy - metabolism |
2 |
|
liver neoplasms - genetics - pathology - therapy |
2 |
|
liver tumour |
2 |
|
lymphocyte |
2 |
|
malignancies |
2 |
|
malignant |
2 |
|
microrna |
2 |
|
molecular |
2 |
|
molecular signaling pathways |
2 |
|
molecular therapeutics |
2 |
|
molecular-targeted therapy |
2 |
|
mtor |
2 |
|
multidrug resistance 1 |
2 |
|
murine double minute 2 |
2 |
|
muscle neoplasms - secondary - therapy |
2 |
|
necrosis |
2 |
|
nutritional status |
2 |
|
nutritional support |
2 |
|
p53 |
2 |
|
parenteral nutrition |
2 |
|
patient selection |
2 |
|
pazopanib |
2 |
|
peptides - therapeutic use |
2 |
|
peritonitis - blood - microbiology - mortality - prevention and control |
2 |
|
phosphoproteins - genetics - metabolism |
2 |
|
platelet |
2 |
|
portal vein - pathology |
2 |
|
proliferation |
2 |
|
protein-energy malnutrition - etiology |
2 |
|
ptk787/zk22258 |
2 |
|
rad001 |
2 |
|
rats, inbred buf |
2 |
|
repeated resection |
2 |
|
review |
2 |
|
rna, messenger - blood - genetics |
2 |
|
sensitivity |
2 |
|
sensitivity and specificity |
2 |
|
sepsis - blood - microbiology - mortality - prevention and control |
2 |
|
serum alpha-fetoprotein |
2 |
|
signaling pathways |
2 |
|
sodium salicylate - pharmacology |
2 |
|
somatostatin |
2 |
|
specificity |
2 |
|
stemcell |
2 |
|
tace |
2 |
|
thigh |
2 |
|
transcription factors - genetics - metabolism |
2 |
|
transplantation |
2 |
|
treatment |
2 |
|
tumor marker |
2 |
|
tumor markers, biological - blood - genetics |
2 |
|
tumor suppressor protein p53 - metabolism |
2 |
|
tumor suppressor proteins - metabolism |
2 |
|
tyrosine kinase receptor b |
2 |
|
ubiquitin-protein ligases - metabolism |
2 |
|
vascular endothelial growth factor a - genetics - metabolism |
2 |
|
vascular neoplasms - secondary - surgery |
2 |
|
von hippel-lindau tumor suppressor protein |
2 |
|
yap |
2 |
|
yap oncogene |
2 |
|
yc-1 |
2 |
|
yttrium |
2 |
|
yttrium radioisotopes - therapeutic use |
2 |
|
advanced stage |
1 |
|
aneurysm, false - diagnosis - etiology - therapy |
1 |
|
angiocidin |
1 |
|
angiography |
1 |
|
antibiotics, antineoplastic - administration and dosage - pharmacology - therapeutic use |
1 |
|
antiviral |
1 |
|
arteriovenous malformations - complications - diagnosis - surgery |
1 |
|
asia - epidemiology |
1 |
|
branched-chain amino acids |
1 |
|
breast cancer |
1 |
|
breast conservation surgery |
1 |
|
breast neoplasms - mortality - pathology - therapy |
1 |
|
carcinoma, hepatocellular - complications - mortality - therapy |
1 |
|
carcinoma, hepatocellular - diagnosis - epidemiology - pathology - therapy |
1 |
|
carcinoma, hepatocellular - etiology - surgery |
1 |
|
carcinoma, hepatocellular - mortality - surgery - therapy |
1 |
|
carcinoma, hepatocellular - pathology - surgery - ultrasonography |
1 |
|
carcinoma, hepatocellular - prevention and control |
1 |
|
carcinoma, hepatocellular - psychology - therapy |
1 |
|
catheter ablation - trends |
1 |
|
chemo-sensitivity |
1 |
|
chinese |
1 |
|
cholecystitis - complications - diagnosis |
1 |
|
combination therapy |
1 |
|
consensus statements |
1 |
|
diagnosis, differential |
1 |
|
downstaging |
1 |
|
doxorubicin - administration and dosage - pharmacology - therapeutic use |
1 |
|
dropout |
1 |
|
drug resistance, neoplasm |
1 |
|
duodenal diseases - diagnosis - etiology - surgery |
1 |
|
duodenoscopy |
1 |
|
duodenum - blood supply |
1 |
|
embolization, therapeutic |
1 |
|
endoscopy |
1 |
|
endoscopy, gastrointestinal - methods |
1 |
|
eortc |
1 |
|
etiology |
1 |
|
g 2/m phase arrest |
1 |
|
gastrectomy |
1 |
|
gastric acid - secretion |
1 |
|
gastrointestinal hemorrhage - diagnosis - etiology |
1 |
|
gastrointestinal hemorrhage - diagnosis - etiology - therapy |
1 |
|
granisetron |
1 |
|
helicobacter infections |
1 |
|
helicobacter pylori |
1 |
|
hepatic encephalopathy |
1 |
|
hepatoma |
1 |
|
hyperthermia, induced |
1 |
|
hypoxia-inducible factor 1, alpha subunit - genetics - metabolism |
1 |
|
intermediate stage |
1 |
|
laparoscopy - trends |
1 |
|
laparotomy |
1 |
|
liver - physiology |
1 |
|
liver failure - etiology - surgery |
1 |
|
liver neoplasms - complications - mortality - therapy |
1 |
|
liver neoplasms - diagnosis - epidemiology - pathology - therapy |
1 |
|
liver neoplasms - etiology - surgery |
1 |
|
liver neoplasms - mortality - surgery - therapy |
1 |
|
liver neoplasms - pathology - physiopathology - surgery |
1 |
|
liver neoplasms - pathology - surgery - ultrasonography |
1 |
|
liver neoplasms - prevention and control |
1 |
|
liver neoplasms - psychology - therapy |
1 |
|
long-term survival |
1 |
|
lyso-thermosensitive liposomal doxorubicin |
1 |
|
major hepatectomy |
1 |
|
mastectomy |
1 |
|
multicenter study |
1 |
|
nausea |
1 |
|
neoangiogenesis |
1 |
|
neoplasm recurrence, local - diagnosis - prevention and control - therapy |
1 |
|
neoplasm recurrence, local - prevention and control |
1 |
|
oncogene protein v-akt - genetics - metabolism |
1 |
|
ondansetron |
1 |
|
ornithine transcarbamylase |
1 |
|
peptic ulcer hemorrhage - etiology - microbiology - surgery |
1 |
|
postoperative complications - surgery |
1 |
|
prevention |
1 |
|
quality of life - psychology |
1 |
|
questionnaire |
1 |
|
questionnaires |
1 |
|
recombinant human arginase |
1 |
|
recommendations |
1 |
|
signal transducers and activators of transcription 3 |
1 |
|
staging system |
1 |
|
stomach - blood supply |
1 |
|
surgical procedures, minimally invasive - trends |
1 |
|
thoracoscopy |
1 |
|
tissue donors - supply and distribution |
1 |
|
treatment algorithm |
1 |
|
ultrasonography, doppler, color |
1 |
|
ultrasonography, interventional |
1 |
|
vagotomy, truncal - methods |
1 |
|
varicose veins - diagnosis |
1 |
|
vascular fistula - diagnosis - etiology - surgery |
1 |
|
vitamin k 2 - therapeutic use |
1 |
|
vitamins - therapeutic use |
1 |
|
vomiting |
1 |
|
waiting lists - mortality |
1 |
